Last reviewed · How we verify

Healthpoint — Portfolio Competitive Intelligence Brief

Healthpoint pipeline: 5 marketed, 0 filed, 1 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

5 marketed 0 filed 1 Phase 3 2 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Collagenase SANTYL® Ointment Collagenase SANTYL® Ointment marketed
Collagenase Santyl Vehicle Collagenase Santyl Vehicle marketed Enzymatic debridement agent Collagen (fibrous protein substrate) Wound Care / Dermatology
Bacitracin Ointment Bacitracin Ointment marketed
Tegaderm Hydrogel Tegaderm Hydrogel marketed Wound Care
Santyl Santyl marketed Other
HP-802-247 HP-802-247 phase 3 CD47 antibody CD47 Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Akeso · 1 shared drug class
  2. Bio-Thera Solutions · 1 shared drug class
  3. MediWound Ltd · 1 shared drug class
  4. Shenzhen Hornetcorn Bio-technology Company, LTD · 1 shared drug class
  5. Takara Bio Inc. · 1 shared drug class
  6. Takeda · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Healthpoint:

Cite this brief

Drug Landscape (2026). Healthpoint — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/healthpoint. Accessed 2026-06-10.

Related